Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jun 1:211:107932.
doi: 10.1016/j.drugalcdep.2020.107932. Epub 2020 Mar 18.

Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs

Ricky N Bluthenthal  1 , Kelsey Simpson  2 , Rachel Carmen Ceasar  2 , Johnathan Zhao  2 , Lynn Wenger  3 , Alex H Kral  3
Affiliations
Clinical Trial

Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs

Ricky N Bluthenthal et al. Drug Alcohol Depend. .

Abstract

Objective: Opioid withdrawal symptoms are widely understood to contribute to health risk but have rarely been measured in community samples of opioid using people who inject drugs (PWID).

Methods: Using targeted sampling methods, 814 PWID who reported regular opioid use (at least 12 uses in the last 30 days) were recruited and interviewed about demographics, drug use, health risk, and withdrawal symptoms, frequency, and pain. Multivariable regression models were developed to examine factors associated with any opioid withdrawal, withdrawal frequency, pain severity, and two important health risks (receptive syringe sharing and non-fatal overdose).

Results: Opioid withdrawal symptoms were reported by 85 % of participants in the last 6 months, with 29 % reporting at least monthly withdrawal symptoms and 35 % reporting at least weekly withdrawal symptoms. Very or extremely painful symptoms were reported by 57 %. In separate models, we found any opioid withdrawal (adjusted odds ratio [AOR] = 2.75, 95 % confidence interval [CI] = 1.52, 5.00) and weekly or more opioid withdrawal frequency (AOR = 1.94; 95 % CI = 1.26, 3.00) (as compared to less than monthly) to be independently associated with receptive syringe sharing while controlling for confounders. Any opioid withdrawal (AOR = 1.71; 95 % CI = 1.04, 2.81) was independently associated with nonfatal overdose while controlling for confounders. In a separate model, weekly or more withdrawal frequency (AOR = 1.69; 95 % CI = 1.12, 2.55) and extreme or very painful withdrawal symptoms (AOR = 1.53; 95 % CI = 1.08, 2.16) were associated with nonfatal overdose as well.

Conclusions: Withdrawal symptoms among PWID increase health risk. Treatment of withdrawal symptoms is urgently needed and should include buprenorphine dispensing.

Keywords: Drug overdose/epidemiology; HCV infections/complications; HIV infections/complications; Heroin dependence/epidemiology; Risk factors; Substance withdrawal syndrome/ prevention & control; heroin/adverse effects.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no conflict of interest to declare.

References

    1. American Psychiatric Association, 2013. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Ed. Arlington, VA.
    1. Barnes DM, Des Jarlais DC, Wolff M, Feelemyer J, Tross S, 2018. A qualitative study of persons who inject drugs but who have never helped others with first injections: How their views on helping contrast with the views of persons who have helped with first injections, and implications for interventions. Harm Reduct J, 15, 43. - PMC - PubMed
    1. Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND, 2011. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J. Addict. Med 5, 175–180. - PMC - PubMed
    1. Bluthenthal RN, Watters JK, 1995. Multimethod research from targeted sampling to HIV risk environments. NIDA Res. Monogr 157, 212–230. - PubMed
    1. Cagle HH, Fisher DG, Senter TP, Thurmond RD, Kastar AJ, 2002. Classifying skin lesions of injection drug users: A method for corroborating disease risk. Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD.

Publication types

MeSH terms